Open Access
E3S Web Conf.
Volume 319, 2021
International Congress on Health Vigilance (VIGISAN 2021)
Article Number 01042
Number of page(s) 7
Published online 09 November 2021
  1. Organisation Mondiale de la Santé. Rapport sur la tuberculose dans le monde 2020 : résumé d’orientation. (Organisation mondiale de la Santé, 2020). [Google Scholar]
  2. Davies, J. & Davies, D. Origins and Evolution of Antibiotic Resistance. Microbiol. Mol. Biol. Rev. MMBR 74, 417–433 2010. [CrossRef] [PubMed] [Google Scholar]
  3. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. The Lancet 356, 1255–1259 2000. [CrossRef] [Google Scholar]
  4. Valadares, R. M. C., Carvalho, W. da S. & Miranda, S. S. de. Association of adverse drug reaction to anti-tuberculosis medication with quality of life in patients in a tertiary referral hospital. Rev. Soc. Bras. Med. Trop. 53, e20190207 (2019). [Google Scholar]
  5. Forget, E. J. & Menzies, D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 5, 231–249 2006. [CrossRef] [PubMed] [Google Scholar]
  6. Tan, W. C., Ong, C. K., Kang, S. C. L. & Razak, M. A. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med. J. Malaysia 62, 143–146 2007. [Google Scholar]
  7. Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). [Google Scholar]
  8. Zoukal, S., Bakana, G. T., Nani, S. & Hassoune, S. Démarche d’élaboration d’une revue systématique. Rev. Marocaine Santé Publique 6, (2019) [Google Scholar]
  9. MedDRA | Medical Dictionary for Regulatory Activities. [Google Scholar]
  10. Bégaud, B. Dictionnaire de pharmaco-épidémiologie. (1995). [Google Scholar]
  11. Hartling, L. et al. Decision Rules for Application of the Newcastle-Ottawa Scale. Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments [Internet] (Agency for Healthcare Research and Quality (US), 2012). [Google Scholar]
  12. Arif I Dela, Tank, N. K. D., Singh, A. P. & Piparva, K. G. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India Off. Organ Indian Chest Soc. 34, 522–526 2017. [CrossRef] [PubMed] [Google Scholar]
  13. Hoa, N. B., Nhung, N. V., Khanh, P. H., Hai, N. V. & Quyen, B. T. T. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam. BMC Res. Notes 8, 809 (2015). [CrossRef] [Google Scholar]
  14. Prasad, R. et al. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. Indian J. Tuberc. 63, 106–114 2016. [CrossRef] [Google Scholar]
  15. Ahmad, N. et al. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients. Am. J. Ther. 25, e533–e540 (2018). [CrossRef] [PubMed] [Google Scholar]
  16. P V, K., Palaian, S., Ojha, P. & P R, S. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal. Pak. J. Pharm. Sci. 21, 51–56 2008. [Google Scholar]
  17. Tak, D. K., Acharya, L. D., Gowrinath, K., Rao Padma, G. M. & Subish, P. Safety evaluation of antitubercular therapy under Revised National Tuberculosis Control Programme in India. J. Clin. Diagn. Res. 3, 1395–1401 2009. [Google Scholar]
  18. Yang, T. W. et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore) 96, e7482 (2017). [CrossRef] [PubMed] [Google Scholar]
  19. Ormerod, L. P. & Horsfield, N. Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment. Tuber. Lung Dis. 77, 37–42 1996. [CrossRef] [Google Scholar]
  20. Aouam, K. et al. Les effets indésirables des antituberculeux: épidémiologie, mécanismes et conduite à tenir. Médecine Mal. Infect. 37, 253–261 2007. [CrossRef] [Google Scholar]
  21. Törün, T. et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 9, 1373–1377 2005. [Google Scholar]
  22. Kouider, M. E. R. I. E. O., Benkhaled, I. D. R. I. S. & Kheloui, Y. A. C. I. N. Les effets secondaires majeurs aux antituberculeux. Rev. Fr. Allergol. 59, 283–284 2019. [CrossRef] [Google Scholar]
  23. Yee, D. et al. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am. J. Respir. Crit. Care Med. 167, 1472–1477 2003. [CrossRef] [PubMed] [Google Scholar]
  24. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Http:// [Google Scholar]
  25. Organisation Mondiale de la Santé. Le traitement de la tuberculose : principes à l’intention des programmes nationaux. WHO/TB/97.220, [Google Scholar]
  26. Union internationale contre la tuberculose et les maladies respiratoires. Guide PIH à la gestion médicale de la tuberculose multirésistante. [Google Scholar]
  27. Intini, E., Kishore, G., Richeldi, L. & Udwadia, Z. F. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us. BMJ Case Rep. 12, (2019). [Google Scholar]
  28. Court, R. et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 105, 688–694 2021 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.